US regulators re-evaluating RSV treatment amid concerns from vaccine skeptics led by RFK Jr. CDC recommends individual-based decision-making on hepatitis B vaccine for infants born to negative mothers. ACIP votes 8 to 3 to lift universal recommendation. beyforetus output triples as Sanofi, AstraZeneca gear up for RSV season.

U.S. regulators are re-evaluating infant RSV antibody treatments following concerns raised by vaccine skeptics, which led Robert F. Kennedy Jr.'s health team to initiate safety inquiries. The CDC's Advisory Committee on Immunization Practices voted 8-3 to retract the universal recommendation for hepatitis B birth-dose vaccine for infants born to hepatitis B surface antigen-negative mothers and suggested individual-based decision-making. If the birth dose is not administered, the initial dose should be given no earlier than two months of age. This review reflects the ongoing re-examination of immunization policies by the current administration. ACIP's decision and related updates can be found on Benzinga.com.